Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | NETTER-1 update: 177Lu-DOTATATE in patients with midgut neuroendocrine tumors

Jonathan Strosberg, MD, Moffitt Cancer Center, Tampa, FL, shares updated results from the Phase III NETTER-1 study (NCT01578239) of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. Previously reported findings demonstrated a significant prolongation of progression-free survival with 177Lu-DOTATATE compared to high-dose octreotide alone. After an 18-month treatment period or at the time of disease progression, patients entered the long-term follow up phase where they could receive further anti-cancer treatment. 200 patients entered this phase, with a median follow-up of over 76 months. The final overall survival results showed a non-statistically significant improvement of 11.7 months in the 177Lu-DOTATATE arm. This result may have been impacted by the high crossover rate of 36% from the control arm to radioligand therapy after progression. No new safety signals emerged during the 5-year long-term follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting

Disclosures

Jonathan Strosberg, MD has consulted for Novartis, and received speaker’s bureau fees from Ipsen.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.